Copyright (c) 2014 AJC
This work is licensed under a Creative Commons Attribution 4.0 International License.
An Investigation into Formation of Impurities During Synthesis of Blonanserin
Corresponding Author(s) : K. Sudarshan Rao
Asian Journal of Chemistry,
Vol. 26 No. 18 (2014): Vol 26 Issue 18
Abstract
During the process development of Blonanserin (1), we have observed formations of unknown impurities are in the final product at enhanced levels which was identified as Des ethyl impurity, di-N-ethylpiperazine impurity, Chloro impurity and des-fluoro impurity. The present work involves detailed optimization studies directed toward the development of an efficient process for the commercial production of Blonanserin substantially free from the chloro impurity and other impurities.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- H. Oka, Y. Noda, Y. Ochi, K. Furukawa, T. Une, S. Kurumiya, K. Hino and T Karasawa, J. Pharmacol. Exp. Ther., 264, 158 (1993).
- Y. Noda, S. Kurumiya, Y. Miura and M. Oka, J. Pharmacol. Exp. Ther., 265, 745 (1993).
- A. Prakash and A.J. Wagstaff, Drugs, 56, 429 (1998); doi:10.2165/00003495-199856030-00011.
- T. Nagai, Y. Noda, T. Une, K. Furukawa, H. Furukawa, Q.M. Kan and T. Nabeshima, Neuroreport, 14, 269 (2003); doi:10.1097/00001756-200302100-00023.
- T. Ochi, M. Sakamoto, A. Minamida, K. Suzuki, T. Ueda, T. Une, H. Toda, K. Matsumoto and Y. Terauchi, Bioorg. Med. Chem. Lett., 15, 1055 (2005); doi:10.1016/j.bmcl.2004.12.028.
- T. Ishibashi, H. Nishikawa, T. Une and H. Nakamura, Folia Pharmacol. Jpn, 132, 351 (2008); doi:10.1254/fpj.132.351.
- E.D. Deeks and G.M. Keating, CNS Drugs, 24, 65 (2010); doi:10.2165/11202620-000000000-00000.
- R. Kumagai and Y. Ichimiya, Psychiatry Clin. Neurosci., 63, 593 (2009); doi: 10.1111/j.1440-1819.2009.01966.x.
- E. Garcia, M. Robert, F. Peris, H. Nakamura, N. Sato and Y. Terazawa, CNS Drugs, 23, 615 (2009); doi:10.2165/00023210-200923070-00006.
- T. Furuse and K. Hashimoto, Ann. Gen. Psychiatry, 9, 17 (2010); doi:10.1186/1744-859X-9-17.
References
H. Oka, Y. Noda, Y. Ochi, K. Furukawa, T. Une, S. Kurumiya, K. Hino and T Karasawa, J. Pharmacol. Exp. Ther., 264, 158 (1993).
Y. Noda, S. Kurumiya, Y. Miura and M. Oka, J. Pharmacol. Exp. Ther., 265, 745 (1993).
A. Prakash and A.J. Wagstaff, Drugs, 56, 429 (1998); doi:10.2165/00003495-199856030-00011.
T. Nagai, Y. Noda, T. Une, K. Furukawa, H. Furukawa, Q.M. Kan and T. Nabeshima, Neuroreport, 14, 269 (2003); doi:10.1097/00001756-200302100-00023.
T. Ochi, M. Sakamoto, A. Minamida, K. Suzuki, T. Ueda, T. Une, H. Toda, K. Matsumoto and Y. Terauchi, Bioorg. Med. Chem. Lett., 15, 1055 (2005); doi:10.1016/j.bmcl.2004.12.028.
T. Ishibashi, H. Nishikawa, T. Une and H. Nakamura, Folia Pharmacol. Jpn, 132, 351 (2008); doi:10.1254/fpj.132.351.
E.D. Deeks and G.M. Keating, CNS Drugs, 24, 65 (2010); doi:10.2165/11202620-000000000-00000.
R. Kumagai and Y. Ichimiya, Psychiatry Clin. Neurosci., 63, 593 (2009); doi: 10.1111/j.1440-1819.2009.01966.x.
E. Garcia, M. Robert, F. Peris, H. Nakamura, N. Sato and Y. Terazawa, CNS Drugs, 23, 615 (2009); doi:10.2165/00023210-200923070-00006.
T. Furuse and K. Hashimoto, Ann. Gen. Psychiatry, 9, 17 (2010); doi:10.1186/1744-859X-9-17.